来氟米特与环磷酰胺治疗难治性肾病综合征的对比性研究

目的对比分析来氟米特与环磷酰胺治疗难治性肾病综合征的临床疗效及安全性。方法选择2008年1月～2009年1月来本院进行治疗的难治性肾病综合征患者112例作为研究对象,随机分为观察组和对照组,每组各56例,对照组采用环磷酰胺加标准激素静脉冲击疗法,观察组给予口服来氟米特加激素疗法。对比分析两组患者治疗后临床疗效及实验室指标。结果治疗后6个月,观察组总缓解率(83.9%)高于对照组(73.2%),差异无统计学意义(P=0.17);观察组尿蛋白定量、CRE、UA、AST和ALT均低于对照组,差异有统计学意义(P<0.05),观察组Alb高于对照组(P<0.05);观察组不良反应发生率(12.5%)低于对照组(28.6%),差异有统计学意义(P<0.05)。结论来氟米特联合激素治疗难治性肾病综合征的效果优于环磷酰胺,不良反应小,值得在临床上进一步研究和推广。

Comparison study of the clinical effectiveness and safe of leflunomide and cyclophosphamide on refractory nephritic syndrome

Objective To compare the clinical effectiveness and safe of leflunomide(LEF) and cyclophosphamide(CTX) on refractory nephritic syndrome.Methods 112 patients with refractory nephritic syndrome were select from 2008 to 2009 as subject.All patients were divided into observation group and control group randomly.There were 56 patients for each group.The control group received CTX and hormone,while the observation group received LEF and hormone.To compare the clinical effectiveness and indexes.Results After 6 months treatment,the total remission rate for observation group(83.9%) was higher than that for control group(73.2%)(P=0.17).The Urine protein,CRE,UA,AST and ALT for observation group were all lower than those for control group(P<0.05).The adverse effect rate for observation group(12.5%) was lower than that for control group(28.6%)(P<0.05).Conclusion The clinical effectiveness and safe of LEF on refractory nephritic syndrome was better than CTX.The new medicine was worth to research and development.